NTV // REUTERS pusht BIO_RAD LABS - 500 Beiträge pro Seite

[SOM.you.]

RE: Bio-Rad

die pushen gerade Bio-rad Labs.
Die Sicherheit des Tests ist nachhaltig anerkannt worden.

Mein Reden ( s. Kaufempfehlung bei 30,50 US$)


SOM

[SOM.you.]

RE: Bio Radfalls noch jemand investiert ist :

Kurs aktuell : 39,70 US$
Kursgewinn seit Empfehlung : + 25 %

Hier die letzten News:
- deutlicher Kapazitätsausbau, Bio-Rad produziert in vielen Werken rund um den Globus Test Kits um die Nachfrage zu befriedigen
- man hat Aufträge für über eine Millionen Test Kits vorliegen für 2001
- erheblicher Anstieg der Umsätze un Gewinne


Hier die AdHoc:

Bio-Rad Laboratories Meets Accelerating Need for Accurate `Mad Cow` Diagnostic Test
Bio-Rad Increases Manufacturing Capacity to One Million Per Month To Meet Demand
120,000 Tests Shipped to Europe Since November, More Than a Million More Ordered
HERCULES, Calif., Jan. 17 /PRNewswire/ -- Bio-Rad Laboratories (Amex: BIO.A; BIO.B), a U.S.-based company, has become the leading player in safeguarding Europe`s food chain in the Continent`s re-ignited fight against Bovine Spongiform Encephalopathy (BSE), commonly known as ``Mad Cow Disease.``

Since November, Bio-Rad has shipped in excess of 120,000 tests. This constitutes more than $2 million in revenue. Bio-Rad has confirmed orders for more than a million of its PLATELIA(TM) BSE diagnostic tests to be delivered to European customers in calendar year 2001. To meet the surging demand for quick and accurate tests, Bio-Rad has increased manufacturing capabilities at its French facilities and now has the capacity to produce one million tests per month. Bio-Rad employees around the world are being mobilized to support the growing list of customers and demands of scaling up testing production and application support.

On January 1, 2001 all countries of the European Union commenced mandatory testing of all beef livestock over the age of 30 months in order to insure the highest quality and safety of the European food chain. Recent media reports indicate that seven million cattle will have to be tested in Europe this year due to concerns over BSE.

BSE was first discovered in the United Kingdom in late 1986. A link has been established between a deadly human disease, variant Creutzfeldt-Jakob Disease (vCJD) and BSE. A cow, even one which has not begun to show symptoms, can be infected with BSE and pose a threat to humans. Approximately 91 people in Europe have contracted vCJD since 1986, with the average life expectancy being 4-6 years after diagnosis.

Since October 2000, the fear of BSE has spread throughout Europe. Thus far, France has discovered more than 160 cases, and others have been discovered in Germany, Spain, Portugal and Italy. Meanwhile, beef prices have dropped across Europe, and fear over vCJD has caused public schools to remove beef from lunch menus. According to one German report, almost half of those surveyed have stopped eating beef.

Bio-Rad`s PLATELIA(TM) BSE test was developed in collaboration with the CEA (Commissariat a l`Energie Atomique) whose test was selected by the European Commission (EC) as one of the three most sensitive and specific tests evaluated in its 1999 study. Bio-Rad`s BSE test has been significantly improved since that initial study and is among the three approved in the most recent EC report of December 29, 2000. Two independent reports commissioned by the Directorate General XXIV, a directorate of the EC, further substantiated Bio-Rad`s test as the preferred test for diagnosing BSE in European cattle. Additionally, Bio-Rad`s test is in a ``screening format`` for use in high throughput environments. Results can be obtained in about 4 hours.

``We have allocated substantial resources to ensure that we can rapidly meet the growing needs for a quick, clear and accurate test,`` said David Schwartz, Bio-Rad`s president and chief executive officer. ``Bio-Rad has long been recognized as a leader in supplying private, institutional and government agencies with the products for detection of serious and dangerous food pathogens and we stand ready to meet the needs of Europe during this crisis.``

Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.

Various statements made within this press release may constitute ``forward-looking statements`` for purposes of the Securities and Exchange Commission`s ``safe harbor`` provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company`s expectations.

SOURCE: Bio-Rad Laboratories


SOM